Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 and SEL-110 in Advanced Mesothelioma
NCT03436732Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Apr 2019
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMB-100 and SVP-rapamycin in malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Grade >=3 Adverse Events Related to Study Drug at Day 85 and Maximum Tolerated Dose at Day 21. Started Feb 2018; status: terminated.
02
Drugs
LMB-100SVP-rapamycin
03
Conditions
malignant pleural mesothelioma (MPM)malignant peritoneal mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03436732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436732.